2017 ERS声明:α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗

2017-11-30 欧洲呼吸学会 Eur Respir J. 2017 Nov 30;50(5).

2017年11月,欧洲呼吸学会(ERS)发布了α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗声明。α1抗胰蛋白酶缺乏是最常见的成人遗传性疾病,主要与肺气肿和肝病风险增加相关。本文主要针对α1抗胰蛋白酶缺乏相关的肺部疾病的诊断和管理的相关内容提出声明建议。

中文标题:

2017 ERS声明:α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗

英文标题:

European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency.

发布机构:

欧洲呼吸学会

发布日期:

2017-11-30

简要介绍:

2017年11月,欧洲呼吸学会(ERS)发布了α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗声明。α1抗胰蛋白酶缺乏是最常见的成人遗传性疾病,主要与肺气肿和肝病风险增加相关。本文主要针对α1抗胰蛋白酶缺乏相关的肺部疾病的诊断和管理的相关内容提出声明建议。

 

拓展指南:肺部疾病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017 ERS声明:α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗)] GetToolGuiderByIdResponse(projectId=1, id=b9a861c001528290, title=2017 ERS声明:α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗, enTitle=European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency., guiderFrom=Eur Respir J. 2017 Nov 30;50(5)., authorId=null, author=, summary=2017年11月,欧洲呼吸学会(ERS)发布了α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗声明。α1抗胰蛋白酶缺乏是最常见的成人遗传性疾病,主要与肺气肿和肝病风险增加相关。本文主要针对α1抗胰蛋白酶缺乏相关的肺部疾病的诊断和管理的相关内容提出声明建议。 , cover=, journalId=null, articlesId=null, associationId=172, associationName=欧洲呼吸学会, associationIntro=欧洲呼吸学会(ERS)是欧洲专业学会组织,是具有广泛基础的拥有100多个国家的大约一万名成员。内容涵盖了基础科学和临床医学。, copyright=0, guiderPublishedTime=Thu Nov 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017年11月,欧洲呼吸学会(ERS)发布了α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗声明。α1抗胰蛋白酶缺乏是最常见的成人遗传性疾病,主要与肺气肿和肝病风险增加相关。本文主要针对α1抗胰蛋白酶缺乏相关的肺部疾病的诊断和管理的相关内容提出声明建议。 </P> <P> </P>拓展指南:<strong>与<font color=red>肺部疾病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=b9a861c001528290" title="2017 ERS声明:α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗" target=_blank>2017 ERS声明:α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6f6d41c000e51395" title="2010TSANZ在澳大利亚和新西兰的儿童和成人的慢性化脓性肺部疾病和支气管扩张症指南" target=_blank>2010TSANZ在澳大利亚和新西兰的儿童和成人的慢性化脓性肺部疾病和支气管扩张症指南</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E8%82%BA%E9%83%A8%E7%96%BE%E7%97%85" target=_blank>有关肺部疾病更多指南</a></ul>, tagList=[TagDto(tagId=26816, tagName=α1抗胰蛋白酶缺乏), TagDto(tagId=19742, tagName=肺部疾病), TagDto(tagId=10804, tagName=肺气肿)], categoryList=[CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3823, appHits=54, showAppHits=0, pcHits=2936, showPcHits=1601, likes=92, shares=1, comments=3, approvalStatus=1, publishedTime=Wed Dec 06 21:31:56 CST 2017, publishedTimeString=2017-11-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Dec 06 21:31:56 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 07:20:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 ERS声明:α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗)])
2017 ERS声明:α1抗胰蛋白酶缺乏肺部疾病的诊断和治疗
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=267498, encodeId=c4c826e49882, content=学习一下谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Dec 07 08:14:13 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267464, encodeId=978b26e4647e, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Dec 07 07:19:22 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267349, encodeId=ada026e34948, content=学习了.值得分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:27:15 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-07 三生有幸9135

    学习一下谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=267498, encodeId=c4c826e49882, content=学习一下谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Dec 07 08:14:13 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267464, encodeId=978b26e4647e, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Dec 07 07:19:22 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267349, encodeId=ada026e34948, content=学习了.值得分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:27:15 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-07 明月清辉

    谢谢分享.学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=267498, encodeId=c4c826e49882, content=学习一下谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Dec 07 08:14:13 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267464, encodeId=978b26e4647e, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Dec 07 07:19:22 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267349, encodeId=ada026e34948, content=学习了.值得分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 06 22:27:15 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-06 1ddf0692m34(暂无匿称)

    学习了.值得分享

    0